Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD.
Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD.
Crit Care Explor. 2024 Oct 1;6(10):e1159. doi: 10.1097/CCE.0000000000001159.
To investigate which independent factor(s) have an impact on the pharmacokinetics of vancomycin in critically ill children, develop an equation to predict the 24-hour area under the concentration-time curve from a trough concentration, and evaluate dosing regimens likely to achieve a 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio (AUC24/MIC) greater than or equal to 400.
Prospective population pharmacokinetic study of vancomycin.
Critically ill patients in quaternary care PICUs.
Children 90 days old or older to younger than 18 years who received IV vancomycin treatment, irrespective of the indication for use, in the ICUs at the University of Maryland Children's Hospital and Texas Children's Hospital were enrolled.
Vancomycin was prescribed at doses and intervals chosen by the treating clinicians.
A median of four serum levels of vancomycin per patient were collected along with other variables for up to 7 days following the first administration. These data were used to characterize vancomycin pharmacokinetics and evaluate the factors affecting the variability in achieving AUC24/MIC ratio greater than or equal to 400 in PICU patients who are not on extracorporeal therapy. A total of 302 children with a median age of 6.0 years were enrolled. A two-compartment model described the pharmacokinetics of vancomycin with the clearance of 2.76 L/hr for a typical patient weighing 20 kg. The glomerular filtration rate estimated using either the bedside Schwartz equation or the chronic kidney disease in children equation was the only statistically significant predictor of clearance among the variables evaluated, exhibiting equal predictive performance. The trough levels achieving AUC24/MIC = 400 were 5.6-10.0 μg/mL when MIC = 1 μg/mL. The target of AUC24/MIC greater than or equal to 400 was achieved in 60.4% and 36.5% with the typical dosing regimens of 15 mg/kg every 6 and 8 hours (q6h and q8h), respectively.
The pharmacokinetics of vancomycin in critically ill children were dependent on the estimated glomerular filtration rate only. Trough concentrations accurately predict AUC24. Typical pediatric vancomycin dosing regimens of 15 mg/kg q6h and q8h will often lead to AUC24/MIC under 400.
研究哪些独立因素会影响危重症患儿万古霉素的药代动力学,建立从谷浓度预测 24 小时浓度-时间曲线下面积的方程,并评估可能达到 24 小时浓度-时间曲线下面积与最低抑菌浓度比值(AUC24/MIC)大于或等于 400 的给药方案。
万古霉素的前瞻性群体药代动力学研究。
四级儿童重症监护 PICUs 的危重症患儿。
90 天至 18 岁以下的接受静脉万古霉素治疗的患儿,无论使用的适应证如何,均在马里兰大学儿童医院和德克萨斯儿童医院的 ICU 中入组。
万古霉素的剂量和间隔由治疗医生选择。
每位患者平均采集 4 个时间点的万古霉素血清水平,同时采集其他变量,在首次给药后最多 7 天内进行。这些数据用于描述万古霉素的药代动力学,并评估影响未接受体外治疗的 PICU 患儿达到 AUC24/MIC 比值大于或等于 400 的因素。共纳入 302 名中位年龄为 6.0 岁的儿童。一个两室模型描述了万古霉素的药代动力学,典型体重为 20kg 的患者的清除率为 2.76L/hr。评估的变量中,只有估计肾小球滤过率(使用床边 Schwartz 方程或儿童慢性肾脏病方程)是清除率的唯一具有统计学意义的预测因子,表现出同等的预测性能。当 MIC=1μg/mL 时,实现 AUC24/MIC=400 的谷浓度为 5.6-10.0μg/mL。以 15mg/kg 每 6 小时(q6h)和每 8 小时(q8h)的典型剂量方案,AUC24/MIC 大于或等于 400 的目标分别在 60.4%和 36.5%的患者中达到。
危重症患儿万古霉素的药代动力学仅取决于估计的肾小球滤过率。谷浓度能准确预测 AUC24。典型的儿科万古霉素剂量方案,即 15mg/kg q6h 和 q8h,常常导致 AUC24/MIC 低于 400。